Top Midday Decliners

MT Newswires Live12-14

Repare Therapeutics (RPTX) reported Thursday results from a phase 1 trial of cancer drugs lunresertib and camonsertib that disappointed investors.

The lunresertib and camonsertib combination achieved a 25.9% objective response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer in the trial. The study included heavily pretreated patients.

Shares slumped 57% following a surge in intraday trading volume to over 3.6 million from a daily average of about 165,000.

Inovio Pharmaceuticals (INO) said Friday it priced an offering of 10 million shares and accompanying warrants to purchase the same number of shares at $3 per share and accompanying warrant.

Shares slumped 39%, with intraday trading volume at over 7.8 million versus the stock's daily average of about 387,000.

Candel Therapeutics (CADL) sank past 30% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to 3.3 million shares at $5.99 per warrant to raise about $80 million in gross proceeds.

More than 15.1 million shares traded intraday compared with a daily average of about 2.4 million.

Price: 1.71, Change: -2.26, Percent Change: -56.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491730119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 02:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491730119","market":"hk","top_or_hot":-1,"title":"Top Midday Decliners","media":"MT Newswires Live","content":"<html><body><p> Repare <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RPTX) reported Thursday results from a phase 1 trial of cancer drugs lunresertib and camonsertib that disappointed investors.</p><p>The lunresertib and camonsertib combination achieved a 25.9% objective response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer in the trial. The study included heavily pretreated patients.</p><p>Shares slumped 57% following a surge in intraday trading volume to over 3.6 million from a daily average of about 165,000.</p><p>Inovio Pharmaceuticals (INO) said Friday it priced an offering of 10 million shares and accompanying warrants to purchase the same number of shares at $3 per share and accompanying warrant.</p><p>Shares slumped 39%, with intraday trading volume at over 7.8 million versus the stock's daily average of about 387,000.</p><p>Candel Therapeutics (CADL) sank past 30% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to 3.3 million shares at $5.99 per warrant to raise about $80 million in gross proceeds.</p><p>More than 15.1 million shares traded intraday compared with a daily average of about 2.4 million.</p><p>Price: 1.71, Change: -2.26, Percent Change: -56.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-14 02:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Repare Therapeutics (RPTX) reported Thursday results from a phase 1 trial of cancer drugs lunresertib and camonsertib that disappointed investors.The lunresertib and camonsertib combination achieved a...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CADL","symbol_name":"Candel Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2491730119","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491730119","pubTimestamp":1734115318,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Repare Therapeutics  reported Thursday results from a phase 1 trial of cancer drugs lunresertib and camonsertib that disappointed investors.The lunresertib and camonsertib combination achieved a 25.9% objective response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer in the trial. The study included heavily pretreated patients.Shares slumped 57% following a surge in intraday trading volume to over 3.6 million from a daily average of about 165,000.Inovio Pharmaceuticals  said Friday it priced an offering of 10 million shares and accompanying warrants to purchase the same number of shares at $3 per share and accompanying warrant.Shares slumped 39%, with intraday trading volume at over 7.8 million versus the stock's daily average of about 387,000.Candel Therapeutics  sank past 30% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to 3.3 million shares at $5.99 per ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CADL":"Candel Therapeutics, Inc.","BK4583":"猴痘概念","BK4539":"次新股","BK4139":"生物科技","RPTX":"Repare Therapeutics Inc.","BK4568":"美国抗疫概念","INO":"伊诺维奥制药"},"translate_title":"午盘跌幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CADL":0.9,"INO":0.9,"RPTX":0.9},"content_text":"Repare Therapeutics (RPTX) reported Thursday results from a phase 1 trial of cancer drugs lunresertib and camonsertib that disappointed investors.The lunresertib and camonsertib combination achieved a 25.9% objective response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer in the trial. The study included heavily pretreated patients.Shares slumped 57% following a surge in intraday trading volume to over 3.6 million from a daily average of about 165,000.Inovio Pharmaceuticals (INO) said Friday it priced an offering of 10 million shares and accompanying warrants to purchase the same number of shares at $3 per share and accompanying warrant.Shares slumped 39%, with intraday trading volume at over 7.8 million versus the stock's daily average of about 387,000.Candel Therapeutics (CADL) sank past 30% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to 3.3 million shares at $5.99 per warrant to raise about $80 million in gross proceeds.More than 15.1 million shares traded intraday compared with a daily average of about 2.4 million.Price: 1.71, Change: -2.26, Percent Change: -56.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491730119"}